非输血依赖型地中海贫血患者报告结局症状测量工具(NTDT-PRO©)的验证
本研究在意大利、黎巴嫩、希腊和泰国48例非输血依赖型β地中海贫血患者中开展为期24周的多中心验证,评估首个为该人群开发的患者报告结局工具NTDT-PRO©。该工具含疲乏/无力与气促2个领域共6个条目,信效度良好,内部一致性高,与SF-36v2及FACT-An相关工具相关性稳健。
要点
- NTDT-PRO©含疲乏/无力与气促2个领域共6个条目,在48例患者中显示有效可靠且一致性良好。
- 基线时多数患者通过NTDT-PRO报告存在症状,完成率≥90%,依从性高。
- 第1周气促与SF-36v2活力维度rs=-0.53,与FACT-An疲乏体验rs=-0.66。
核心结论
- NTDT-PRO©在非输血依赖型β地中海贫血患者中显示有效、可靠且稳定,可用于临床实践和纵向临床研究,尤其在预期患者健康相关生活质量发生变化的试验中。
- 需要进一步研究以充分支持该工具的有效性。
研究设计与样本
- 多中心验证研究,为期24周,纳入意大利、黎巴嫩、希腊和泰国48例非输血依赖型β地中海贫血患者。
- 大多数患者为女性(68.8%),中位年龄34.5岁(范围18-52岁);66.7%诊断为β地中海贫血中间型,中位诊断后时间22年(范围0-43年)。
主要发现
- NTDT-PRO含2个领域(疲乏/无力与气促)共6个条目,有效可靠且一致性良好。
- 基线时多数患者通过NTDT-PRO报告症状存在,依从性高,≥90%完成NTDT-PRO工具。
- 两两相关分析中所有条目均呈正相关。
- 第1周气促与SF-36v2活力维度rs=-0.53,气促与FACT-An疲乏体验rs=-0.66。
- 内部一致性:疲乏/无力Cronbach alpha为0.91,气促Spearman-Brown系数为0.78;组内相关系数疲乏/无力为0.88和0.97,气促为0.92和0.98。
临床怎么用
- 作者认为NTDT-PRO在临床实践和纵向临床研究中具有实用性,尤其在预期患者健康相关生活质量发生变化的试验中。
局限性
- 需要进一步研究以充分支持该工具的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study demonstrates the quantitative characteristics of the first patient-reported outcome (PRO) tool developed for patients with nontransfusion-dependent β-thalassemia (NTDT), the NTDT-PRO© . A multicenter validation study was performed over 24 weeks, involving 48 patients from Italy, Lebanon, Greece, and Thailand. Most patients were female (68.8%), with a median age of 34.5 years (range, 18-52); 66.7% were diagnosed with β-thalassemia intermedia, and median time since diagnosis was 22 years (range, 0-43). The NTDT-PRO comprises 6 items across 2 domains (Tiredness/Weakness and Shortness of Breath [SoB]), and was valid and reliable, with good consistency. At baseline, most patients reported symptoms as present via the NTDT-PRO, and were highly compliant, ≥90% completing the NTDT-PRO tool. In a pairwise correlation analysis, all items were positively correlated. Correlations between NTDT-PRO and existing tools-36-Item Short Form Health Survey version 2 (SF-36v2) and Functional Assessment of Cancer Therapy-Anemia (FACT-An)-were assessed at weeks 1, 3, and 12; robust correlations were seen between SoB and SF-36v2-Vitality (rs = -0.53), and between SoB and Fact-An-Fatigue Experience (rs = -0.66) at week 1. Internal consistency was high for both Tiredness/Weakness (Cronbach alpha, 0.91) and SoB (Spearman-Brown coefficient, 0.78); intraclass correlation coefficients were high (Tiredness/Weakness, 0.88 and 0.97; SoB, 0.92 and 0.98), demonstrating stability. Further studies are required to fully support the validity of this tool, this study demonstrated the usefulness of the NTDT-PRO in the clinical setting and for longitudinal clinical research, particularly in trials where patient health-related quality of life is expected to change.
引用
- Taher A, Cappellini MD, Viprakasit V, et al. Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© ). Am J Hematol. 2018. PMID: 30394570. doi:10.1002/ajh.25344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。